natgillin/translations-raw huggingface dataset:
beregnes fra de foreliggende data) domslignende reaktion Metabolisme og ernæring
(cannot be estimated from available data)
Nerve - systemet
Nervous System Disorders
Opkastning Mave - og abdominalsmerte r Dyspepsi Flatulens
Vomiting Gastrointestinal and abdominal pains Dyspepsia Flatulence
Levernekrose (meget sjældent progredierende til livstruende leversvigt) (se pkt.
Liver necrosis (very rarely progressing to life-threatening hepatic failure) (see section 4.4)
4. 4)
Photosensitivity reactions (see section 4.4)
Organklasse
103 System Organ
Almindelig ≥ 1/ 100 til < 1/ 10
Common
Ikke almindelig ≥ 1/ 1. 000 til < 1/ 100
≥ 1/ 1 000 to <
Sjælden ≥ 1/ 10. 000 til < 1/ 1. 000
≥ 1/ 10 000 to <
Meget sjælden < 1/ 10. 000
< 1/ 10 000
Ukendt hyppihed (kan ikke
not known
beregnes fra de foreliggende data) Hud og subkutane væv
Toxic epidermal necrolysis (potentially life- threatening)
Udslæt Pruritus Urticaria
(cannot be estimated from available data)
Fotosensitivitets - reaktioner (se pkt.
Musculoskeletal, Musculoskeletal
4. 4)
Myalgia
Petekkier Erythema multiforme Erythema nodosum Stevens - Johnson - syndrom (potentielt livstruende) Toksisk epidermal nekrolyse (potentielt livstruende)
Muscular
Knogler, led, muskler og bindevæv
Connective Tissue and Bone Disorders
Muskel - og skeletsmerter (f. eks. ekstremitetssmer - ter, rygsmerter og brystsmerter) Artralgier
pain (e. g. extremity pain, back pain, chest pain) Arthralgia
Myalgier Artritis Øget muskeltonus og muskelkramper
Arthritis Increased muscle tone and cramping
4. 4)
weakness Tendinitis Tendon rupture (predominantly Achilles tendon) (see section 4.4) Exacerbation of symptoms of myasthenia gravis (see section 4.4)
105 4. 9 Overdosering
4.9 Overdose
Der er set plasmidmedieret resistens kodet via qnr- gener.
Plasmid- mediated resistance encoded by qnr-genes has been reported.
106 EUCAST- rekommendationer
EUCAST Recommendations
Neisseria gonorrhoeae Neisseria meningitidis Ikke- artsrelaterede breakpoints *
Neisseria gonorrhoeae Neisseria meningitidis Non-species-related breakpoints *
R > 0, 06 mg / R > 0, 06 mg / R > 1 mg/ l
R > 0.06 mg/ L R > 0.06 mg/ L R > 1 mg/ L
De skal kun bruges for arter, som ikke har fået et arts- specifikt breakpoint, og ikke for de arter, hvor testning af følsomhed ikke anbefales.
They are for use only for species that have not been given a species-specific breakpoint and not for those species
ALMINDELIGE FØLSOMME ARTER Aerobe grampositive mikroorganismer Bacillus anthracis (1) Aerobe gramnegative mikroorganismer Aeromonas spp.
106 COMMONLY SUSCEPTIBLE SPECIES Aerobic Gram-positive micro-organisms Bacillus anthracis (1) Aerobic Gram-negative micro-organisms Aeromonas spp.
Yersinia pestis Anaerobe mikroorganismer Mobiluncus Andre mikroorganismer Chlamydia trachomatis ($) Chlamydia pneumoniae ($) Mycoplasma hominis ($) Mycoplasma pneumoniae ($) ARTER, HVOR ERHVERVET RESISTENS KAN VÆRE ET PROBLEM Aerobe grampositive mikroorganismer Enterococcus faecalis ($) Staphylococcus spp. * (2) Aerobe gramnegative mikroorganismer Acinetobacter baumannii+ Burkholderia cepacia+ * Campylobacter spp. + * Citrobacter freundii * Enterobacter aerogenes Enterobacter cloacae * Escherichia coli * Klebsiella oxytoca Klebsiella pneumoniae * Morganella morganii * Neisseria gonorrhoeae * Proteus mirabilis * Proteus vulgaris * Providencia spp.
Pseudomonas aeruginosa* Pseudomonas fluorescens Serratia marcescens*
Pseudomonas aeruginosa * Pseudomonas fluorescens Serratia marcescens * Anaerobe mikroorganismer Peptostreptococcus spp.
Anaerobic micro-organisms Peptostreptococcus spp.
Propionibacterium acnes ORGANISMER MED NATURLIG RESISTENS Aerobe grampositive mikroorganismer Actinomyces
Propionibacterium acnes
108 Enteroccus faecium Listeria monocytogenes Aerobe gramnegative mikroorganismer Stenotrophomonas maltophilia Anaerobe mikroorganismer Undtagen ovennævnte Andre mikroorganismer Mycoplasma genitalium Ureaplasma urealitycum * Der er dokumenteret klinisk effekt for følsomme isolater ved godkendte indikationer + Resistensgrad ≥ 50% i et eller flere EU- lande ($):
107 INHERENTLY RESISTANT ORGANISMS Aerobic Gram-positive micro-organisms Actinomyces Enteroccus faecium Listeria monocytogenes Aerobic Gram-negative micro-organisms Stenotrophomonas maltophilia Anaerobic micro-organisms Excepted as listed above Other micro-organisms Mycoplasma genitalium Ureaplasma urealitycum * Clinical efficacy has been demonstrated for susceptible isolates in approved clinical indications. + Resistance rate ≥ 50% in one or more EU countries ($):
Den behandlende læge henvises til nationale og/ eller internationale konsensusdokumenter vedrørende behandling af anthrax.
The treating physician should refer to national and / or international consensus documents regarding treatment of anthrax.
Der er fundet små koncentrationer af fire metabolitter, som blev identificeret som: desethylenciprofloxacin (M 1), sulphociprofloxacin (M 2), oxociprofloxacin (M 3) og
108 Low concentrations of four metabolites have been reported, which were identified as: desethyleneciprofloxacin (M 1), sulphociprofloxacin (M 2), oxociprofloxacin (M 3) and formylciprofloxacin (M 4).
Ciprofloxacin er kendt for at være en moderat hæmmer af CYP 450 1A2- iso- enzymer.
Ciprofloxacin is known to be a moderate inhibitor of the CYP 450 1A2 iso-enzymes.
110 6.
109 6.
Ryst posen med et let tryk på siden af posen.
Take the prescribed amount of sachets.
Åbn derefter posen som angivet, og tag indholdet med det samme.
Shake the sachet applying slight pressure to the walls.
Ingen særlige forholdsregler.
Then tear the sachet open as indicated and take the contents directly.
[MM/ ÅÅÅÅ] [Udfyldes nationalt]
[To be completed nationally]
Ciprofloxacin Bayer og tilhørende navne (se bilag I) 500 mg oral suspension i enkeltdosisposer [Se bilag I – Udfyldes nationalt]
Ciprofloxacin Bayer and associated names (see Annex I) 500 mg oral suspension in single-dose sachets [See Annex I - To be completed nationally]
4. 4 og 5. 1).
The Ciprofloxacin Bayer 500 mg oral suspension in single-dose sachets are indicated for the treatment of the following infections (see sections 4.4 and 5.1).
112 • Infektioner i hud og bløddele forårsaget af gramnegative bakterier
• Infections of the skin and soft tissue caused by Gram-negative bacteria
• Malign ekstern otitis
111 • Malignant external otitis
2- 4 uger (akut) til 4- 6 uger (kronisk)
weeks (acute) to 4 to6 weeks (chronic)
500 mg som éngangsdosis
113 Indications
10 mg/ kg op til 15 mg/ kg legemsvægt to gange
10 mg/ kg body weight twice daily to 15 mg/ kg
60 dage
60 days from the
dagligt, maksimalt 500 mg pr. dosis.
body weight twice daily with a maximum of 500 mg per dose.
Ved sådanne infektioner skal iprofloxacin gives sammen med andre passende antibakterielle midler.
In such infections ciprofloxacin must be co-administered with other appropriate antibacterial agents.
116 Rejsediaré Ved valget af ciprofloxacin skal der tages hensyn til resistensen over for ciprofloxacin hos relevante patogener i de lande, der besøges.
115 Travellers’ diarrhoea The choice of ciprofloxacin should take into account information on resistance to ciprofloxacin in relevant pathogens in the countries visited.
117 Allerede 48 timer efter start af behandlingen med ciprofloxacin kan der forekomme tendinitis og seneruptur (specielt af akillessenen), af og til bilateralt.
116 Tendinitis and tendon rupture (especially Achilles tendon), sometimes bilateral, may occur with ciprofloxacin, as soon as the first 48 hours of treatment.
118 Cytokrom P450 Ciprofloxacin hæmmer CYP1A2 og kan derfor medføre øgede serumkoncentrationer af lægemidler, som gives samtidigt, og som metaboliseres af dette enzym (f. eks. teofyllin, clozapin, ropinirol og tizanidin).
117 Cytochrome P450 Ciprofloxacin inhibits CYP1A2 and thus may cause increased serum concentration of concomitantly administered substances metabolised by this enzyme (e. g. theophylline, clozapine, ropinirole, tizanidine).
119 Methotrexat
Methotrexate
Teofyllin
118 Theophylline
120 Amning Ciprofloxacin udskilles i modermælk.
Lactation Ciprofloxacin is excreted in breast milk.
4. 7 Virkning på evnen til at føre motorkøretøj eller betjene maskiner
119 4.7 Effects on ability to drive and use machines
Organklasse
120 System Organ
Organklasse
121 System Organ
Det er indberettet, at en overdosis på 12 g har medført lette toksiske symptomer.
122 An overdose of 12 g has been reported to lead to mild symptoms of toxicity.
124 * Ikke- artsrelaterede breakpoints er primært blevet bestemt på grundlag af PK/ PD- data, og er uafhængige af fordelingerne af MIC for specifikke arter.
1 Staphylococcus spp. - breakpoints for ciprofloxacin relate to high dose therapy. * Non-species-related breakpoints have been determined mainly on the basis of PK/ PD data and are independent of MIC distributions of specific species.
ALMINDELIGE FØLSOMME ARTER Aerobe grampositive mikroorganismer Bacillus anthracis (1) Aerobe gramnegative mikroorganismer Aeromonas spp.
124 COMMONLY SUSCEPTIBLE SPECIES Aerobic Gram-positive micro-organisms Bacillus anthracis (1) Aerobic Gram-negative micro-organisms Aeromonas spp.
Yersinia pestis Anaerobe mikroorganismer Mobiluncus Andre mikroorganismer Chlamydia trachomatis ($) Chlamydia pneumoniae ($) Mycoplasma hominis ($) Mycoplasma pneumoniae ($) ARTER, HVOR ERHVERVET RESISTENS KAN VÆRE ET PROBLEM Aerobe grampositive mikroorganismer Enterococcus faecalis ($) Staphylococcus spp. * (2) Aerobe gramnegative mikroorganismer Acinetobacter baumannii+ Burkholderia cepacia+ * Campylobacter spp. + * Citrobacter freundii * Enterobacter aerogenes Enterobacter cloacae * Escherichia coli * Klebsiella oxytoca Klebsiella pneumoniae * Morganella morganii * Neisseria gonorrhoeae * Proteus mirabilis * Proteus vulgaris * Providencia spp.
Yersinia pestis Anaerobic micro-organisms Mobiluncus Other micro-organisms Chlamydia trachomatis ($) Chlamydia pneumoniae ($) Mycoplasma hominis ($) Mycoplasma pneumoniae ($) SPECIES FOR WHICH ACQUIRED RESISTANCE MAY BE A PROBLEM Aerobic Gram-positive micro-organisms Enterococcus faecalis($) Staphylococcus spp. *(2) Aerobic Gram-negative micro-organisms Acinetobacter baumannii+ Burkholderia cepacia+* Campylobacter spp. +* Citrobacter freundii* Enterobacter aerogenes Enterobacter cloacae * Escherichia coli* Klebsiella oxytoca Klebsiella pneumoniae* Morganella morganii* Neisseria gonorrhoeae* Proteus mirabilis* Proteus vulgaris* Providencia spp.
126 Enteroccus faecium Listeria monocytogenes Aerobe gramnegative mikroorganismer Stenotrophomonas maltophilia Anaerobe mikroorganismer Undtagen ovennævnte Andre mikroorganismer Mycoplasma genitalium Ureaplasma urealitycum * Der er dokumenteret klinisk effekt for følsomme isolater ved godkendte indikationer + Resistensgrad ≥ 50% i et eller flere EU- lande ($):
125 INHERENTLY RESISTANT ORGANISMS Aerobic Gram-positive micro-organisms Actinomyces Enteroccus faecium Listeria monocytogenes Aerobic Gram-negative micro-organisms Stenotrophomonas maltophilia Anaerobic micro-organisms Excepted as listed above Other micro-organisms Mycoplasma genitalium Ureaplasma urealitycum * Clinical efficacy has been demonstrated for susceptible isolates in approved clinical indications. + Resistance rate ≥ 50% in one or more EU countries ($):
Ciprofloxacin har en lav proteinbinding (20- 30%).
Pprotein binding of ciprofloxacin is low (20-30%).
Der er fundet små koncentrationer af fire metabolitter, som blev identificeret som: desethylenciprofloxacin (M 1), sulphociprofloxacin (M 2), oxociprofloxacin (M 3) og
126 Low concentrations of four metabolites have been reported, which were identified as: desethyleneciprofloxacin (M 1), sulphociprofloxacin (M 2), oxociprofloxacin (M 3) and formylciprofloxacin (M 4).
128 6.
127 6.
Ciprofloxacin Bayer og tilhørende navne (se bilag I) 50 mg/ ml granulat og solvens til oral suspension [Se bilag I – Udfyldes nationalt]
Ciprofloxacin Bayer and associated names (see Annex I) 50 mg/ mL granules and solvent for oral suspension [See Annex I - To be completed nationally]
50 mg/ ml granulat og solvens til oral suspension [Udfyldes nationalt]
Granules and solvent for oral suspension [To be completed nationally]
4. 4 og 5. 1).
The Ciprofloxacin Bayer 50 mg/ mL oral suspension is indicated for the treatment of the following infections (see sections 4.4 and 5.1).
130 • Infektioner i hud og bløddele forårsaget af gramnegative bakterier
• Infections of the skin and soft tissue caused by Gram-negative bacteria
• Malign ekstern otitis
129 • Malignant external otitis
131 Voksne
Adults
Daglig dosis i ml (antal 5 ml måleskeer)
Daily dose in mL (Number of 5-mL
Behandlingsvarighed (inklusiv evt. initial parenteral behandling med ciprofloxacin)
including initial parenteral treatment with ciprofloxacin) Infections of the lower
Infektioner i de nedre luftveje (iht. sværhedsgrad og organisme)
respiratory tract
500 mg to gange dagligt op til 750 mg to gange dagligt
twice daily
10 ml to gange dagligt op til 15 ml to gange dagligt (to 5 ml måleskeer to gange dagligt op til tre 5 ml måleskeer to gange dagligt)
(two 5-mL measuring spoonfuls twice daily up to three 5-mL measuring spoonfuls twice daily)
Infektioner i de Akut exacerbation øvre luftvej (iht. af kronisk sinusitis sværhedsgrad og organisme)
chronic sinusitis
Kronisk suppurativ otitis media
otitis media
7- 14 dage
28 days up to 3
Malign ekstern otitis
external otitis
750 mg to gange dagligt
daily
15 ml to gange dagligt (tre 5 ml måleskeer to gange dagligt)
(three 5-mL measuring spoonfuls twice daily)
28 dage op til 3 måneder
Urinary tract
Urinvejsinfektioner Ukompliceret (iht. sværhedsgrad cystitis og organisme)
Uncomplicated
250 mg to gange dagligt op til 500 mg to gange dagligt
250 mg twice
5 ml to gange dagligt op til 10 ml to gange dagligt (én 5 ml måleske to gange dagligt op til to 5 ml måleskeer to gange dagligt)
5-mL twice daily to
132
cystitis
Indikationer
daily to 500 mg
Daglig dosis i mg
10 mL twice daily
Daglig dosis i ml (antal 5 ml måleskeer)
twice daily
Behandlingsvarighed (inklusiv evt. initial parenteral behandling med ciprofloxacin)
(one 5-mL measuring
Hos præ- menopausale kvinder kan der gives 500 mg som éngangsdosis svarende til 10 ml éngangsdosis = to 5 ml måleskeer som éngangsdosis
spoonful twice daily up to two 5-mL measuring spoonfuls twice daily) In pre-menopausal women, 500 mg single dose may be used corresponding to 10 mL single dose = two 5-mL measuring spoonfuls as a single dose
Kompliceret cystitis, Ukompliceret
Complicated
500 mg to gange dagligt
500 mg twice
ml to gange dagligt (to 5 ml
10 mL twice daily
pyelonephritis
cystitis, Uncomplicated pyelonephritis
måleskeer to
daily
gange dagligt)
(two 5-mL measuring spoonfuls twice daily)
Kompliceret pyelonephritis
Complicated
500 mg to gange
500 mg twice
10 ml to gange dagligt op til
10 mL twice daily to
Mindst 10 dage, i nogle tilfælde kan
at least 10 days, it
dagligt op til 15 ml to gange
pyelonephritis
behandlingen
daily to 750 mg
750 mg to
15-mL twice daily
dagligt
twice daily
fortsætte i længere
for longer than 21 days in some specific circumstances (such as abscesses)
gange
500 mg twice
(to 5 ml
10 mL twice daily to
end 21 dage (f. eks.
2 to 4 weeks
dagligt
daily to 750 mg
måleskeer to gange dagligt op til tre
15-mL twice daily
ved abscesser)
(acute) to 4 to 6
5
twice daily
ml måleskeer to gange dagligt)
(two 5-mL measuring spoonfuls twice daily up to three 5-mL measuring spoonfuls twice daily)
Prostatitis
131 Indications
500 mg to gange
Daily dose in mg
10 ml to gange 2- 4 uger (akut) til 4- 6 dagligt op til uger (kronisk)
Daily dose in mL (Number of 5-mL
dagligt op til 15 ml to gange
measuring spoonfuls)
750 mg to
(potentially
dagligt
Gonococcal
gange
500 mg as a
(to 5 ml
1 day (single
dagligt
infections
måleskeer to gange dagligt op til tre
uretritis and cervicitis
5
single dose
ml måleskeer to gange dagligt)
corresponding to two 5- mL measuring spoonfuls as a single dose
Genitale
dose)
Urethritis og
Epididymo-
500 mg som
500 mg twice
10 ml som
10 mL twice daily to
1 dag (éngangsdosis)
at least 14 days
infektioner
orchitis and
cervicitis, som skyldes gonokokker
daily to 750 mg
éngangsdosis éngangsdosis svarende til to 5 ml måleskeer som éngangsdosis
15-mL twice daily
Epididymoorchitis og underlivsbetændelse
pelvic inflammatory diseases
500 mg to 10 ml to gange gange dagligt op til dagligt op til 15 ml to gange 750 mg to dagligt gange (to 5 ml dagligt måleskeer to gange dagligt op til tre 5 ml måleskeer to gange dagligt)
(two 5-mL measuring spoonfuls twice daily up to three 5-mL measuring spoonfuls twice daily)
Mindst 14 dage
Infections of
133 Indikationer
Diarrhoea
Daglig dosis i mg
500 mg twice
Daglig dosis i ml (antal 5 ml måleskeer)
10 mL twice daily
Behandlingsvarighed (inklusiv evt. initial parenteral behandling med ciprofloxacin)
1 day
Gastrointestinale og intraabdominale infektioner
the gastro- intestinal tract and intra- abdominal infections
Diaré forårsaget af patogene bakterier, herunder Shigella spp., bortset fra Shigella dysenteriae type 1 og empirisk behandling af svær rejsediaré
caused by bacterial pathogens including Shigella spp. other than Shigella dysenteriae type 1 and empirical treatment of severe travellers’ diarrhoea
500 mg to gange dagligt
daily
10 ml to gange dagligt (to 5 ml måleskeer to gange dagligt)
(two 5-mL measuring spoonfuls twice daily)
1 dag
5 days
Diaré forårsaget af Shigella dysenteriae type 1
caused by Shigella dysenteriae type 1
500 mg to gange dagligt
mg twice daily
Tyfus
Typhoid fever
Intraabdominale infektioner, som skyldes gramnegative bakterier
Intra-abdominal
500 mg to gange dagligt op til 750 mg to gange dagligt
500 mg twice
10 ml to gange dagligt op til 15 ml to gange dagligt (to 5 ml måleskeer to gange dagligt op til tre 5 ml måleskeer to gange dagligt)
10 mL twice daily to
5- 14 dage
5 to 14 days
Infektioner i hud og
infections due to
bløddele
daily to 750 mg
500 mg to gange dagligt op til 750 mg to gange dagligt
15-mL twice daily
10 ml to gange dagligt op til 15 ml to gange dagligt (to 5 ml måleskeer to gange dagligt op til tre 5 ml måleskeer to gange dagligt)
Gram-negative bacteria
7 til 14 dage
twice daily
134 Indikationer
132 Indications
Behandlingsvarighed (inklusiv evt. initial parenteral behandling med ciprofloxacin)
Total duration of treatment
Infektioner i knogler og led
measuring spoonfuls)
500 mg to gange dagligt op til 750 mg to gange dagligt
(potentially
10 ml to gange dagligt op til 15 ml to gange dagligt (to 5 ml måleskeer to gange dagligt op til tre 5 ml måleskeer to gange dagligt)
including initial parenteral treatment with ciprofloxacin) Infections of the skin and soft
Højst i 3 måneder
10 mL twice daily to
Behandling af infektioner eller profylakse over for infektioner hos patienter med neutropeni Ciprofloxacin skal gives sammen med andre antibakterielle stoffer i henhold til officielle retningslinjer.
daily to 750 mg
Behandlingen bør fortsættes i hele neutropeniperioden
Bone and joint infections
Profylakse ved invasive infektioner, som skyldes Neisseria meningitidis
500 mg twice
500 mg som éngangsdosis
10 mL twice daily to
10 ml som éngangsdosis svarende til to 5 ml måleskeer som éngangsdosis
max. of 3 months
1 dag (éngangsdosis)
daily to 750 mg
Inhalationsanthrax, profylakse efter eksponering og kurativ behandling til patienter, som kan behandles oralt, når det er klinisk passende.
15-mL twice daily
500 mg to gange dagligt
twice daily
10 ml to gange dagligt (to 5 ml målesskeer to gange dagligt)
(two 5-mL measuring spoonfuls twice daily up to three 5-mL measuring spoonfuls twice daily)
60 dage efter bekræftelse af eksponering for Bacillus anthracis
Treatment of infections or
Børn og unge
prophylaxis of infections in
Indikationer
daily to 750 mg
Daglig dosis i mg og ml
15-mL twice daily
Behandlingsvarighed
be continued over
(inklusiv evt. parenteral behandling med ciprofloxacin) Cystisk fibrose
neutropenic patients Ciprofloxacin should be co- administered with appropriate antibacterial agent(s) in accordance to official guidance.
20 mg/ kg legemsvægt to gange dagligt, maksimalt 750 mg pr. dosis, svarende til 0, 4 ml/ kg legemsvægt to gange dagligt, maksimalt 15 ml pr. dosis
(two 5-mL measuring spoonfuls twice daily up to three 5-mL measuring spoonfuls twice daily)
10- 14 dage
10 mL as a single dose
Komplicerede urinvejsinfektioner
infections due to Neisseria meningitidis
10 mg/ kg op til 20 mg/ kg legemsvægt to gange dagligt, maksimalt 750 mg pr. dosis, svarende til
corresponding to two 5- mL measuring spoonfuls as a single dose
10- 21 dage
10 mL twice daily
135
daily
og pyelonephritis
Daily dose in mg and in mL
0, 2 ml/ kg legemsvægt to gange dagligt til 0, 4 ml/ kg legemsvægt to gange dagligt, maksimalt 15 ml pr. dosis
treatment (potentially including initial parenteral treatment with ciprofloxacin) Cystic fibrosis
Inhalationsanthrax, profylakse efter eksponering og kurativ behandling til patienter, som kan behandles oralt, når det er klinisk passende.
20 mg/ kg body weight twice daily with a maximum of 750 mg per dose, corresponding to a 0.4 mL/ kg body weight twice daily with a maximum of 15-mL per dose
Behandlingen skal påbegyndes så hurtigt som muligt efter mistanke om eller bekræftet eksponering.
treatment (potentially including initial parenteral treatment with ciprofloxacin) Complicated urinary tract infections and pyelonephritis
10 mg/ kg op til 15 mg/ kg legemsvægt to gange dagligt, maksimalt 500 mg pr. dosis, svarende til 0, 2 ml/ kg legemsvægt to gange dagligt til 0, 3 ml/ kg legemsvægt to gange dagligt, maksimalt 10 ml pr. dosis
10 mg/ kg body weight twice daily to 20 mg/ kg body weight twice daily with a maximum of 750 mg per dose, corresponding to a 0.2 mL/ kg body weight twice daily to 0.4 mL/ kg body weight twice daily with a maximum of 15-mL per dose
20 mg/ kg legemsvægt to gange dagligt, maksimalt 750 mg pr. dosis, svarende til 0, 4 ml/ kg legemsvægt to gange dagligt, maksimalt 15 ml pr. dosis
20 mg/ kg body weight twice daily with a maximum of 750 mg per dose, corresponding to a 0.4 mL/ kg body weight twice daily with a maximum of 15-mL per dose
≤ 124
< 124
Indgivelsesmåde
134 Method of administration
136 I svære tilfælde, eller hvis patienten ikke kan indtage den orale suspension (f. eks. patienter, som får enteral ernæring), bør behandlingen påbegyndes med intravenøs ciprofloxacin, indtil det er muligt at skifte til oral indgift.
In severe cases or if the patient is unable to take oral suspension (e. g. patients on enteral nutrition), it is recommended to commence therapy with intravenous ciprofloxacin until a switch to oral administration is possible.
2, 5 ml suspension) indeholder ca.
½ measuring spoonful (approx 2.5-mL suspension) provides approx.
125 mg ciprofloxacin.
125 mg ciprofloxacin.
5, 0 ml suspension) indeholder ca.
1 measuring spoonful (approx 5.0 mL suspension) provides approx.
250 mg ciprofloxacin.
250 mg ciprofloxacin.
Der må ikke tilsættes noget til den færdigblandede ciprofloxacin- suspension.
No additions should be made to the mixed final ciprofloxacin suspension.
Infektioner i knogler og led Ciprofloxacin bør anvendes i kombination med andre antibakterielle lægemidler, afhængigt af resultaterne af de mikrobiologiske undersøgelser.
135 Infections of the bones and joints Ciprofloxacin should be used in combination with other antimicrobial agents depending on the results of the microbiological documentation.
137 Børn og unge Anvendelsen af ciprofloxacin til børn og unge skal ske i henhold til tilgængelig officiel vejledning.
Children and adolescents The use of ciprofloxacin in children and adolescents should follow available official guidance.
Ved tegn på tendinitis (f. eks. smertefuld hævelse eller inflammation), skal behandlingen med ciprofloxacin seponeres.
136 At any sign of tendinitis (e. g. painful swelling, inflammation), ciprofloxacin treatment should be discontinued.
138 Centralnervesystemet Quinoloner er kendt for at kunne udløse krampeanfald eller sænke krampetærsklen.
Central Nervous System Quinolones are known to trigger seizures or lower the seizure threshold.